CA2801168A1 - 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators - Google Patents

3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators Download PDF

Info

Publication number
CA2801168A1
CA2801168A1 CA2801168A CA2801168A CA2801168A1 CA 2801168 A1 CA2801168 A1 CA 2801168A1 CA 2801168 A CA2801168 A CA 2801168A CA 2801168 A CA2801168 A CA 2801168A CA 2801168 A1 CA2801168 A1 CA 2801168A1
Authority
CA
Canada
Prior art keywords
dihydro
oxo
chromeno
pyrrol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2801168A
Other languages
English (en)
French (fr)
Inventor
Ramakanth Sarabu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2801168A1 publication Critical patent/CA2801168A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2801168A 2010-06-17 2011-06-14 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators Abandoned CA2801168A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35561910P 2010-06-17 2010-06-17
US61/355,619 2010-06-17
PCT/EP2011/059783 WO2011157682A1 (en) 2010-06-17 2011-06-14 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators

Publications (1)

Publication Number Publication Date
CA2801168A1 true CA2801168A1 (en) 2011-12-22

Family

ID=44266428

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2801168A Abandoned CA2801168A1 (en) 2010-06-17 2011-06-14 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators

Country Status (10)

Country Link
US (1) US8178689B2 (cg-RX-API-DMAC7.html)
EP (1) EP2582706A1 (cg-RX-API-DMAC7.html)
JP (1) JP5844355B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130120993A (cg-RX-API-DMAC7.html)
CN (1) CN102947311B (cg-RX-API-DMAC7.html)
BR (1) BR112012032235A2 (cg-RX-API-DMAC7.html)
CA (1) CA2801168A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012010668A (cg-RX-API-DMAC7.html)
RU (1) RU2603191C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011157682A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ709362A (en) * 2012-12-25 2019-07-26 Hua Medicine Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1h-pyrazol-3-ylamine
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN112888480A (zh) * 2018-10-24 2021-06-01 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒疾病的新型三环化合物
CN113493442B (zh) * 2020-04-03 2024-11-08 天津药物研究院有限公司 作为葡萄糖激酶活化剂的吡咯烷酮衍生物及其制备方法和用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138622A3 (en) 1983-10-18 1986-05-14 E.I. Du Pont De Nemours And Company 8-substituted pyrazolopentathiepins and related compounds
JPS6284064A (ja) 1985-10-09 1987-04-17 Shionogi & Co Ltd ３−パ−フルオロアルキル−５−ヒドロキシイソオキサゾ−ル類
JPH0477477A (ja) 1990-07-18 1992-03-11 Takeda Chem Ind Ltd チアジアゾール酢酸誘導体の製造法
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
IL116507A (en) 1991-11-13 1997-08-14 Schering Ag Pyrazole derivatives
US5498190A (en) 1994-06-27 1996-03-12 Handsontoys, Inc. Flexible foam construction toy and method of manufacturing same
JPH08151386A (ja) 1994-09-27 1996-06-11 Takeda Chem Ind Ltd 複素環エチルチオセフェム化合物、その製造法および抗菌組成物
YU66000A (sh) 1998-04-30 2003-12-31 Agouron Pharmaceuticals Inc. Antipikovirusna jedinjenja, njihovo dobijanje i upotreba
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
WO2001005783A1 (en) 1999-07-15 2001-01-25 Pharmacopeia, Inc. Bradykinin b1 receptor antagonists
US7329679B2 (en) 2000-01-27 2008-02-12 Schering Aktiengesellschaft 1,2 Diarylbenzimidazoles and their pharmaceutical use
KR100548901B1 (ko) 2000-05-08 2006-02-02 에프. 호프만-라 로슈 아게 치환된 페닐아세트아미드 및 그의 글루코키나제활성화제로서의 용도
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2003232204B8 (en) 2002-04-26 2009-07-30 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
PL215132B1 (pl) 2002-06-27 2013-10-31 Novo Nordisk As Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
AU2003287038A1 (en) 2002-10-09 2004-05-04 The Board Of Trustees Of The University Of Illinois METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO (2, 3-b) FURAN AND RELATED COMPOUNDS
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
KR20050105488A (ko) 2003-02-26 2005-11-04 반유 세이야꾸 가부시끼가이샤 헤테로아릴카바모일벤젠 유도체
EP1682524A1 (en) 2003-10-24 2006-07-26 Aventis Pharmaceuticals, Inc. Novel keto-oxadiazole derivatives as cathepsin inhibitors
JP4542550B2 (ja) 2003-10-27 2010-09-15 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｃｒ−２アンタゴニスト塩
MXPA06007667A (es) 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
CA2554686A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
EP1725523A4 (en) 2004-03-16 2007-10-10 Wyeth Corp IONIC CHANNEL MODULATORS
AU2005223610B2 (en) 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR100672184B1 (ko) * 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
JP2008521864A (ja) 2004-12-03 2008-06-26 トランステック・ファーマ、インコーポレイテッド ヘテロ芳香族グルコキナーゼ活性化剤
WO2006064286A1 (en) 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors
JP2009500377A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
KR100965040B1 (ko) 2005-07-11 2010-06-21 미쓰비시 타나베 파마 코퍼레이션 옥심 유도체 및 그의 제조 방법
CN101263131B (zh) 2005-07-14 2013-04-24 特兰斯特克药品公司 脲葡糖激酶活化剂
CA2621227A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007053503A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
US20070197532A1 (en) 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
JP5236499B2 (ja) 2006-01-27 2013-07-17 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤
CA2647208C (en) 2006-03-24 2014-05-13 Array Biopharma Inc. Glucokinase activators
WO2007115968A2 (en) 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Process for the preparation of a glucokinase activator
PT2463283E (pt) 2006-04-20 2014-08-27 Pfizer Prod Inc Compostos heterocíclicos de fenil amido condensados para a prevenção e tratamento de doenças mediadas pela glucoquinase
EP2019824A2 (en) 2006-04-28 2009-02-04 Transtech Pharma, Inc. Benzamide glucokinase activators
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
CN101490064B (zh) * 2006-07-06 2012-10-10 百时美施贵宝公司 新颖葡萄糖激酶活化剂及其使用方法
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
JP2009544648A (ja) 2006-07-24 2009-12-17 エフ．ホフマン−ラ ロシュ アーゲー グルコキナーゼ活性化剤としてのピラゾール類
WO2008111473A1 (ja) 2007-03-07 2008-09-18 Kyorin Pharmaceutical Co., Ltd. グルコキナーゼ活性化物質
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators

Also Published As

Publication number Publication date
BR112012032235A2 (pt) 2019-09-24
KR20130120993A (ko) 2013-11-05
RU2012156706A (ru) 2014-07-27
EP2582706A1 (en) 2013-04-24
US8178689B2 (en) 2012-05-15
JP2013532146A (ja) 2013-08-15
HK1178532A1 (zh) 2013-09-13
CN102947311B (zh) 2015-11-25
RU2603191C2 (ru) 2016-11-27
WO2011157682A1 (en) 2011-12-22
CN102947311A (zh) 2013-02-27
US20110313002A1 (en) 2011-12-22
JP5844355B2 (ja) 2016-01-13
MX2012010668A (es) 2012-10-03

Similar Documents

Publication Publication Date Title
US7741327B2 (en) Pyrrolidinone glucokinase activators
US8258134B2 (en) Pyridazinone glucokinase activators
US8178689B2 (en) Tricyclic compounds
US20130131113A1 (en) Pyridone glucokinase activators
HK1178532B (en) 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators
US20120142705A1 (en) Isatin and oxindole compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160513

FZDE Discontinued

Effective date: 20180614